Neomorph

Neomorph, Inc. is a venture-backed biotechnology company based in San Diego, California. The company specializes in discovering and developing innovative medicines targeting previously ‘undruggable’ proteins using proprietary molecular glue degrader technology. Its leadership team includes recognized experts from academia and industry with deep experience in targeted protein degradation. Neomorph has raised significant funding ($109 million Series A) and maintains key collaborations with major pharmaceutical companies such as Biogen and Novo Nordisk to develop novel therapeutics for oncology, cardiometabolic disorders, rare diseases, and other indications. The company’s pipeline breadth or individual program details are not publicly disclosed; its programs are believed to be preclinical or IND-enabling at this time.